Arena BioWorks Wants To Address Inefficiency Of Early R&D Finance

Incubator Will Use Hub-And-Spoke Model

Backed with $500m to look into the mechanistic underpinnings of unmet medical needs, Arena BioWorks will employ a hub-and-spoke model to incubate biotechs around a central technology hub.

Arena
Arena BioWorks will put discovery and company creation under one roof • Source: Shutterstock

Broad Institute co-founder Stuart Schreiber is teaming up with an all-star list of scientists and financial backers to found Arena BioWorks, which Schreiber said is intended to let scientists focus on developing their hypotheses rather than seeking government grants and then later on, if their research yields something of therapeutic potential, venture capital funding.

Key Takeaways
  • Arena BioWorks will seek to fund researcher-driven science into mechanistic understanding of disease that will be allowed to develop over long timeframes.

Based in Cambridge, MA, the institute will support basic scientific research into the mechanisms of human disease and the translation...

More from Strategy

More from Business

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By 

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.